Spruce Biosciences (SPRB) Competitors

Spruce Biosciences (NASDAQ:SPRB) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Which has more volatility and risk, SPRB or PMN?

Spruce Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Do institutionals and insiders believe in SPRB or PMN?

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is SPRB or PMN more profitable?

Promis Neurosciences has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	-555.23%	-62.10%	-47.49%
Promis Neurosciences	N/A	-266.69%	-131.59%

Which has preferable earnings and valuation, SPRB or PMN?

Promis Neurosciences has lower revenue, but higher earnings than Spruce Biosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	1.02	-$47.92M	-$99.25	-0.09
Promis Neurosciences	N/A	N/A	$2.78M	-$0.21	-2.69

Do analysts rate SPRB or PMN?

Spruce Biosciences presently has a consensus target price of $131.25, suggesting a potential upside of 1,366.48%. Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 666.96%. Given Spruce Biosciences' higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to SPRB or PMN?

In the previous week, Spruce Biosciences and Spruce Biosciences both had 4 articles in the media. Spruce Biosciences' average media sentiment score of -0.04 beat Promis Neurosciences' score of -0.50 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Spruce Biosciences beats Promis Neurosciences on 8 of the 13 factors compared between the two stocks.